Suppr超能文献

MG53:精准治疗心肌病的新主角。

MG53: A new protagonist in the precise treatment of cardiomyopathies.

机构信息

College of Exercise and Health, Shenyang Sport University, Shenyang 110102, Liaoning, PR China.

Innovation Institute, China Medical University, Shenyang 110122, Liaoning, PR China.

出版信息

Biochem Pharmacol. 2024 Apr;222:116057. doi: 10.1016/j.bcp.2024.116057. Epub 2024 Feb 15.

Abstract

Cardiomyopathies (CMs) are highly heterogeneous progressive heart diseases characterised by structural and functional abnormalities of the heart, whose intricate pathogenesis has resulted in a lack of effective treatment options. Mitsugumin 53 (MG53), also known as Tripartite motif protein 72 (TRIM72), is a tripartite motif family protein from the immuno-proteomic library expressed primarily in the heart and skeletal muscle. Recent studies have identified MG53 as a potential cardioprotective protein that may play a crucial role in CMs. Therefore, the objective of this review is to comprehensively examine the underlying mechanisms mediated by MG53 responsible for myocardial protection, elucidate the potential role of MG53 in various CMs as well as its dominant status in the diagnosis and prognosis of human myocardial injury, and evaluate the potential therapeutic value of recombinant human MG53 (rhMG53) in CMs. It is expected to yield novel perspectives regarding the clinical diagnosis and therapeutic treatment of CMs.

摘要

心肌疾病(CMs)是一类具有高度异质性的进行性心脏疾病,其特征为心脏结构和功能异常,其复杂的发病机制导致缺乏有效的治疗选择。Mitsugumin 53(MG53),也称为三结构域蛋白 72(TRIM72),是免疫蛋白质组文库中表达主要在心脏和骨骼肌的三聚体基序家族蛋白。最近的研究表明,MG53 是一种潜在的心脏保护蛋白,可能在 CMs 中发挥关键作用。因此,本综述的目的是全面研究 MG53 介导的心肌保护的潜在机制,阐明 MG53 在各种 CMs 中的潜在作用及其在人类心肌损伤的诊断和预后中的主导地位,以及评估重组人 MG53(rhMG53)在 CMs 中的潜在治疗价值。预计这将为 CMs 的临床诊断和治疗提供新的视角。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验